Malondialdehyde (MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in subjects with familial hypercholesterolemia

Basit Öğe Kaydı
dc.contributor.authorPirinccioglu, Ayfer Gozu
dc.contributor.authorGokalp, Deniz
dc.contributor.authorPirinccioglu, Mihdiye
dc.contributor.authorKizil, Goksel
dc.contributor.authorKizil, Murat
dc.date.accessioned2024-04-24T16:11:03Z
dc.date.available2024-04-24T16:11:03Z
dc.date.issued2010
dc.departmentDicle Üniversitesien_US
dc.description.abstractObjective: Familial hypercholesterolemia (FH) is clinically characterized by elevated total and low-density lipoprotein (LDL) cholesterol levels in plasma, which has high risk for developing atherosclerosis. Increased oxidative stress (OS) and FH have been related to atherosclerosis. The study aims to evaluate oxidative stress in patients with hypercholesterolemia by measuring lipid peroxidation and protein carbonyl (PCO) levels in these patients. PCO in these patients may provide a new diagnostic biomarker for oxidative damage in atherosclerosis. Design and method: Total cholesterol (Tc), low-density lipoprotein-cholesterol (LDL-c), triglyceride (TG), high-density lipoprotein-cholesterol (HDL-c), lipoprotein(a) (Lp-a) levels and carotid intima-media thickness were measured to evaluate characteristics of patients (11 homozygous and 25 heterozygous) with FH. 25 age-gender-BMI matched healthy control subjects were included in the study for comparison. Results: MDA and PCO levels were significantly higher in homozygous patients compared with those of heterozygous and controls and it was found that they are positively correlated with LDL-c, Tc, Lp-a and IMT while negatively correlated with HDL-c. The heterozygous group also had significantly higher MDA and PCO levels compared with controls. Conclusion: The data obtained could be important for understanding the alterations presented by FH and could be related to their increased risk of developing atherosclerosis. To our knowledge, measurements of PCO in patients with FH are not recorded before and this may be used as a biomarker for protein oxidation, which may play a role in the increased cardiovascular risk of patients with FH. (C) 2010 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.en_US
dc.identifier.doi10.1016/j.clinbiochem.2010.07.022
dc.identifier.endpage1224en_US
dc.identifier.issn0009-9120
dc.identifier.issn1873-2933
dc.identifier.issue15en_US
dc.identifier.pmid20691171en_US
dc.identifier.scopus2-s2.0-77956757897en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1220en_US
dc.identifier.urihttps://doi.org/10.1016/j.clinbiochem.2010.07.022
dc.identifier.urihttps://hdl.handle.net/11468/15245
dc.identifier.volume43en_US
dc.identifier.wosWOS:000282204400008en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Science Ltden_US
dc.relation.ispartofClinical Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHypercholesterolemiaen_US
dc.subjectFamilialen_US
dc.subjectOxidative Stressen_US
dc.subjectLipid Peroxidationen_US
dc.subjectMalondialdehydeen_US
dc.subjectProtein Carbonylationen_US
dc.subjectAtherosclerosisen_US
dc.titleMalondialdehyde (MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in subjects with familial hypercholesterolemiaen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu